A bioengineered probiotic for the oral delivery of a peptide Kv1.3 channel blocker to treat rheumatoid arthritis.
- 2023-01-03
- Proceedings of the National Academy of Sciences of the United States of America 120(2)
- Yuqing Wang
- Duolong Zhu
- Laura C Ortiz-Velez
- Jacob L Perry
- Michael W Pennington
- Joseph M Hyser
- Robert A Britton
- Christine Beeton
- PubMed: 36595694
- DOI: 10.1073/pnas.2211977120
Study Design
- Population
- healthy rats
- Methods
- A genetically engineered probiotic delivery system in Lactobacillus reuteri to secrete the Kv1.3 potassium blocker ShK-235 (LrS235); single oral gavage and daily oral gavage in rat disease models
Engineered microbes for the delivery of biologics are a promising avenue for the treatment of various conditions such as chronic inflammatory disorders and metabolic disease. In this study, we developed a genetically engineered probiotic delivery system that delivers a peptide to the intestinal tract with high efficacy. We constructed an inducible system in the probiotic Lactobacillus reuteri to secrete the Kv1.3 potassium blocker ShK-235 (LrS235). We show that LrS235 culture supernatants block Kv1.3 currents and preferentially inhibit human T effector memory (TEM) lymphocyte proliferation in vitro. A single oral gavage of healthy rats with LrS235 resulted in sufficient functional ShK-235 in the circulation to reduce inflammation in a delayed-type hypersensitivity model of atopic dermatitis mediated by TEM cells. Furthermore, the daily oral gavage of LrS235 dramatically reduced clinical signs of disease and joint inflammation in rats with a model of rheumatoid arthritis without eliciting immunogenicity against ShK-235. This work demonstrates the efficacy of using the probiotic L. reuteri as a novel oral delivery platform for the peptide ShK-235 and provides an efficacious strategy to deliver other biologics with great translational potential.
Research Insights
the daily oral gavage of LrS235 dramatically reduced clinical signs of disease and joint inflammation in rats with a model of rheumatoid arthritis
- Effect
- Beneficial
- Effect size
- Large
preferentially inhibit human T effector memory (TEM) lymphocyte proliferation in vitro
- Effect
- Beneficial
- Effect size
- Moderate